Mikhail Lichinitser
Impact in
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Papers in
- Oncology 34
- HER2/EGFR in Cancer Research 11
- Colorectal Cancer Treatments and Studies 9
- Cancer Treatment and Pharmacology 7
- Cancer Immunotherapy and Biomarkers 4
- Bone health and treatments 3
-
- Gastric Cancer Management and Outcomes 5
- Advanced Breast Cancer Therapies 3
- Co-authors
- Werner Scheithauer (4 shared papers)Arié Figer (3 shared papers)Stephen John Clarke (3 shared papers)Sheryl L. Koski (3 shared papers)Tsai‐Shen Yang (3 shared papers)Leonard B. Saltz (3 shared papers)Jim Cassidy (3 shared papers)Félix Couture (3 shared papers)
- Journals
- Journal of Clinical Oncology (12 papers)Annals of Oncology (6 papers)European Journal of Cancer (5 papers)The Lancet Oncology (5 papers)Melanoma Research (2 papers)
- Partner nations
- RussiaUnited StatesUnited Kingdom
In The Last Decade
Mikhail Lichinitser
56 papers receiving 17.4k citations
Mikhail Lichinitser's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 11.0k
- Cancer Research 3.0k
- Pulmonary and Respiratory Medicine 3.8k
- Radiology, Nuclear Medicine and Imaging 2.1k
- Hepatology 717
Countries citing papers authored by Mikhail Lichinitser
This map shows the geographic impact of Mikhail Lichinitser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikhail Lichinitser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikhail Lichinitser more than expected).
Fields of papers citing papers by Mikhail Lichinitser
This network shows the impact of papers produced by Mikhail Lichinitser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikhail Lichinitser. The network helps show where Mikhail Lichinitser may publish in the future.
Co-authors
The 25 scholars most cited alongside Mikhail Lichinitser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Hit paper breakdown → | 2005 | 4136 |
| 2 | Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study Hit paper breakdown → | 2008 | 2480 |
| 3 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Hit paper breakdown → | 2018 | 1503 |
| 4 | Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study Hit paper breakdown → | 2010 | 1244 |
| 5 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2010 | 1002 |
| 6 | Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer Hit paper breakdown → | 2009 | 838 |
| 7 | Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 724 |
| 8 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 668 |
| 9 | Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Hit paper breakdown → | 2009 | 641 |
| 10 | Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2010 | 515 |
| 11 | Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial Hit paper breakdown → | 2010 | 469 |
| 12 | Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2014 | 395 |
| 13 | 2008 | 375 | |
| 14 | 2013 | 364 | |
| 15 | 2004 | 322 | |
| 16 | 2012 | 280 | |
| 17 | 2013 | 270 | |
| 18 | 2012 | 228 | |
| 19 | 2015 | 220 | |
| 20 | 2013 | 178 |
About Mikhail Lichinitser
Mikhail Lichinitser is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Allergy and Genetics, having authored 57 papers that have together received 18.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (11 papers), Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (7 papers), Gastric Cancer Management and Outcomes (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Estrogen and related hormone effects (3 papers), Bone health and treatments (3 papers) and Advanced Breast Cancer Therapies (3 papers). The work is most often cited by research in Oncology (11.0k citations), Cancer Research (3.0k citations), Pulmonary and Respiratory Medicine (3.8k citations), Radiology, Nuclear Medicine and Imaging (2.1k citations) and Hepatology (717 citations). Mikhail Lichinitser has collaborated with scholars based in Russia, United States and United Kingdom. Frequent co-authors include Werner Scheithauer, Arié Figer, Stephen John Clarke, Sheryl L. Koski, Tsai‐Shen Yang, Leonard B. Saltz, Jim Cassidy, Félix Couture, Fernando Rivera and Florin Sirzén. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, The Lancet Oncology and Melanoma Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.